We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Clonidine Reduces Risk of Surgery in Heart Patients

By HospiMedica staff writers
Posted on 10 Aug 2004
A study has found that patients with or at risk for heart disease can reduce the risk of complications and death due to inadequate blood flow to the heart by taking the anti-hypertensive drug clonidine before noncardiac surgery. More...
The findings were reported in the August 2004 issue of Anesthesiology.

This is the second drug that researchers have added to the list of inexpensive preventive measures available to heart patients before noncardiac surgery. The first drug was the beta blocker atenolol, which blocks stress hormones in the brain from stimulating the heart.

The clonidine study involved 190 male patients scheduled to undergo noncardiac surgery who had been diagnosed with coronary artery disease or had at least two of five risk factors for cardiac disease: age 60 or over, hypertension, smoking within a year, cholesterol of 240 or greater, and diabetes. The surgeries performed included orthopedic, head and neck, abdominal, and others. A total of 125 patients received a 0.2 mg oral table of clonidine the night before surgery, a transdermal patch of clonidine the night before surgery, and a 0.2 mg tablet one hour before surgery. A control group received only placebos. The followup after four years showed a death rate of 15% in the clonidine group vs 29% in the placebo group.

The researchers concluded that patients with or at risk for coronary artery disease who undergo noncardiac surgery should be given either atenolol or clonidine before surgery. "Drug therapy to prevent blocked arteries prevents the start of a chain of events leading to heart attack and death,” said lead researcher Arthur Wallace, M.D., Ph.D., associate professor of anesthesia and perioperative care, University of California, San Francisco (USA).




Related Links:
U. of California, San Francisco

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Ultrasound System
FUTUS LE
Radiology System
Riviera SPV AT
Silver Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.